To determine whether iASPP-deficiency accelerates cancer development by attenuating anti-tumor immunity in a different cancer type, we employed the KrasLSL−G12D/+ model of lung adenocarcinoma (Fig. 5A). Here, PPP1R13L is linked to neoplasm.